Literature DB >> 25384965

Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.

Naoki Iwamoto1, Serena Vettori2, Britta Maurer2, Matthias Brock2, Elena Pachera2, Astrid Jüngel2, Maurizio Calcagni3, Renate E Gay2, Michael L Whitfield4, Jörg H W Distler5, Steffen Gay2, Oliver Distler2.   

Abstract

OBJECTIVES: To investigate the role of microRNA-193b-3p (miR-193b) in the vascular pathophysiology of systemic sclerosis (SSc).
METHODS: Expression of miR-193b in skin biopsies and fibroblasts from patients with SSc and normal healthy (NH) controls were determined by real-time PCR. Transfection with miR-193b precursor and inhibitor were used to confirm targets of miR-193b. Proliferative effects of urokinase-type plasminogen activator (uPA) were determined by water-soluble tetrazolium salt-1 assay and by analysis of proliferating cell nuclear antigen expression. Fluorescence activated cell sorting analysis was performed to investigate the effect of uPA on apoptosis. For inhibition of the uPA-cellular receptor for uPA (uPAR) pathway, uPAR neutralising antibodies and low molecular weight uPA were used.
RESULTS: We found that miR-193b was downregulated in SSc fibroblasts and skin sections as compared with NH controls. The expression of miR-193b was not affected by major profibrotic cytokines and hypoxia. Induction of miR-193b in SSc fibroblasts suppressed, and accordingly, knockdown of miR-193b increased the levels of messenger RNA and protein for uPA. uPA was found to be upregulated in SSc as compared with NH controls in a transforming growth factor-β dependent manner, and uPA was strongly expressed in vascular smooth muscle cells in SSc skin section. Interestingly, uPA induced cell proliferation and inhibited apoptosis of human pulmonary artery smooth muscle cells, and these effects were independent of uPAR signalling.
CONCLUSIONS: In SSc, the downregulation of miR-193b induces the expression of uPA, which increases the number of vascular smooth muscle cells in an uPAR-independent manner and thereby contributes to the proliferative vasculopathy with intimal hyperplasia characteristic for SSc. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Arterial Hypertension; Autoimmune Diseases; Systemic Sclerosis

Mesh:

Substances:

Year:  2014        PMID: 25384965     DOI: 10.1136/annrheumdis-2014-205326

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

Review 1.  Is there evidence for vasculitis in systemic sclerosis?

Authors:  Lesley Ann Saketkoo; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 2.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  J Autoimmun       Date:  2017-05-16       Impact factor: 7.094

Review 3.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 4.  Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.

Authors:  Paula S Ramos
Journal:  J Scleroderma Relat Disord       Date:  2019-07-03

Review 5.  New insights into the epigenetics of inflammatory rheumatic diseases.

Authors:  Esteban Ballestar; Tianlu Li
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

Review 6.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

7.  Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis.

Authors:  Irene Soffritti; Maria D'Accolti; Gloria Ravegnini; Maria-Cristina Arcangeletti; Clara Maccari; Flora De Conto; Adriana Calderaro; Elisabetta Caselli
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

8.  MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Francesco Trevisani; Michele Ghidini; Alessandro Larcher; Andrea Lampis; Hazel Lote; Paolo Manunta; Maria Teresa Sciarrone Alibrandi; Laura Zagato; Lorena Citterio; Giacomo Dell'Antonio; Cristina Carenzi; Giovambattista Capasso; Massimo Rugge; Paolo Rigotti; Roberto Bertini; Luciano Cascione; Alberto Briganti; Andrea Salonia; Fabio Benigni; Chiara Braconi; Matteo Fassan; Jens Claus Hahne; Francesco Montorsi; Nicola Valeri
Journal:  Br J Cancer       Date:  2016-11-01       Impact factor: 7.640

9.  Deregulation of miR-193b affects the growth of colon cancer cells via transforming growth factor-β and regulation of the SMAD3 pathway.

Authors:  Kaiming Wu; Zhenxian Zhao; Jun Ma; Jianhui Chen; Jianjun Peng; Shibin Yang; Yulong He
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

Review 10.  MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis.

Authors:  Yisha Li; Jing Huang; Muyao Guo; Xiaoxia Zuo
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-09-11       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.